Clinical trial
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent…
NCT00381797 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00381797 |
|---|---|
| Title | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma |
| Official title | Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma |
| Intervention type | Biological, Drug, Radiation |
| Interventions | Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride |
| Enrollment | 97 |
| Start date | Aug 1, 2006 |
| Primary completion | Oct 1, 2015 |
| Completion | Oct 1, 2015 |
| First posted | Sep 28, 2006 |
| Last update posted | Nov 28, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: